TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway

Am J Physiol Renal Physiol. 2013 Nov 15;305(10):F1477-90. doi: 10.1152/ajprenal.00182.2013. Epub 2013 Sep 18.

Abstract

Transforming growth factor (TGF)-β has been associated with podocyte injury; we have examined its effect on podocyte bioenergetics. We studied transformed mouse podocytes, exposed to TGF-β1, using a label-free assay system, Seahorse XF24, which measures oxygen consumption rates (OCR) and extracellular acidification rates (ECAR). Both basal OCR and ATP generation-coupled OCR were significantly higher in podocytes exposed to 0.3-10 ng/ml of TGF-β1 for 24, 48, and 72 h. TGF-β1 (3 ng/ml) increased oxidative capacity 75%, and 96% relative to control after 48 and 72 h, respectively. ATP content was increased 19% and 30% relative to control after a 48- and 72-h exposure, respectively. Under conditions of maximal mitochondrial function, TGF-β1 increased palmitate-driven OCR by 49%. Thus, TGF-β1 increases mitochondrial oxygen consumption and ATP generation in the presence of diverse energy substrates. TGF-β1 did not increase cell number or mitochondrial DNA copy number but did increase mitochondrial membrane potential (MMP), which could explain the OCR increase. Reactive oxygen species (ROS) increased by 32% after TGF-β1 exposure for 48 h. TGF-β activated the mammalian target of rapamycin (mTOR) pathway, and rapamycin reduced the TGF-β1-stimulated increases in OCR, ECAR, ATP generation, cellular metabolic activity, and protein generation. Our data suggest that TGF-β1, acting, in part, via mTOR, increases mitochondrial MMP and OCR, resulting in increased ROS generation and that this may contribute to podocyte injury.

Keywords: TGF-β1; bioenergetics; extracellular acidification rate; mitochondria; oxygen consumption rate; podocyte.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Antigens, Polyomavirus Transforming / genetics
  • Antigens, Polyomavirus Transforming / metabolism
  • Apoptosis / drug effects
  • Biosensing Techniques
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Fatty Acids / metabolism
  • Glycolysis / drug effects
  • Humans
  • Hydrogen-Ion Concentration
  • Intracellular Signaling Peptides and Proteins / genetics
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Membrane Potential, Mitochondrial / drug effects
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Mice, Transgenic
  • Mitochondria / drug effects*
  • Mitochondria / enzymology
  • Mitochondria / pathology
  • Oxidative Phosphorylation / drug effects*
  • Podocytes / drug effects*
  • Podocytes / enzymology
  • Podocytes / pathology
  • Protein Kinase Inhibitors / pharmacology
  • Reactive Oxygen Species / metabolism*
  • Recombinant Proteins / pharmacology
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism*
  • Time Factors
  • Transforming Growth Factor beta1 / pharmacology*

Substances

  • Antigens, Polyomavirus Transforming
  • Fatty Acids
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • NPHS2 protein
  • Protein Kinase Inhibitors
  • Reactive Oxygen Species
  • Recombinant Proteins
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • Adenosine Triphosphate
  • mTOR protein, mouse
  • TOR Serine-Threonine Kinases